GSK-Vir drug works against all Omicron variants - study
GSK
1,353.50p
16:40 14/11/24
GlaxoSmithKline and Vir Biotechnology on Tuesday said their antibody Covid-19 treatment was effective against all mutations of the Omicron variant, according to early-stage studies.
FTSE 100
8,071.19
16:49 14/11/24
FTSE 350
4,459.02
16:38 14/11/24
FTSE All-Share
4,417.25
16:54 14/11/24
Pharmaceuticals & Biotechnology
19,794.96
16:38 14/11/24
The preclinical data showed the sotrovimab treatment was effective against the 37 known mutations of the Omicron variant, GSK said in a statement.
“These pre-clinical data demonstrate the potential for our monoclonal antibody to be effective against the latest variant, Omicron, plus all other variants of concern defined to date by the WHO, and we look forward to discussing these results with regulatory authorities around the world,” it added.
VIR CEO said he was confident that sotrovimab “will continue to provide significant benefit for the early treatment of patients hoping to avoid the most severe consequences of Covid-19".